Saltar al contenido
Merck

Documentos clave

Ver Toda la documentación

M9020

Mecamylamine hydrochloride

≥98% (TLC), powder, nAChR antagonist

Sinónimos:

2-(Methylamino)isocamphane hydrochloride, Inversine, N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine hydrochloride

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C11H21N · HCl
Número CAS:
826-39-1
Peso molecular:
203.75
NACRES:
NA.77
PubChem Substance ID:
24277851
UNSPSC Code:
12352116
EC Number:
212-555-8
MDL number:
MFCD00151462
Form:
powder
Quality level:
200
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Mecamylamine hydrochloride,

form

powder

Quality Level

200

solubility

ethanol: 122 mg/mL, H2O: 47 mg/mL, isopropanol: 476 mg/mL, glycerol: 95 mg/mL

originator

AstraZeneca

SMILES string

Cl.[H][C@@]12CC[C@@]([H])(C1)C(C)(NC)C2(C)C

InChI

1S/C11H21N.ClH/c1-10(2)8-5-6-9(7-8)11(10,3)12-4;/h8-9,12H,5-7H2,1-4H3;1H/t8-,9+,11?;/m1./s1

InChI key

PKVZBNCYEICAQP-CIISUUNXSA-N

Gene Information

human ... CHRNA1(1134), CHRNA10(57053), CHRNA2(1135), CHRNA3(1136), CHRNA4(1137), CHRNA5(1138), CHRNA6(8973), CHRNA7(1139), CHRNA9(55584), CHRNB1(1140), CHRNB2(1141), CHRNB3(1142), CHRNB4(1143)

Application

Mecamylamine hydrochloride has been used as an additive in extracellular saline during current-clamp recordings to reduce synaptic input. It has also been used as a non-selective nicotinic acetyl choline receptor blocker in aortic body neurons and in MLO-Y4 cells.

Biochem/physiol Actions

Noncompetitive nicotinic acetylcholine receptor antagonist; preferentially blocks nicotinic receptors at autonomic ganglia; crosses blood-brain barrier.

Features and Benefits

This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Disclaimer

Solutions are stable to autoclaving.

Still not finding the right product?

Explore all of our products under

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000453973
0000453973
0000437820
0000437820
0000130932

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Contenido relacionado

Product Information Sheet - M9020

Product Information Sheet

M I Damaj et al.
The Journal of pharmacology and experimental therapeutics, 291(3), 1284-1291 (1999-11-24)
Pharmacological mechanisms involved in nicotine-induced seizures were investigated in mice by testing the ability of several nicotinic agonists in producing seizures after peripheral administration. In addition, nicotinic antagonists such as hexamethonium, mecamylamine, dihydro-beta-erythroidine, and methyllycaconitine citrate (MLA) were used in
G Panagis et al.
Synapse (New York, N.Y.), 35(1), 15-25 (1999-12-01)
In the present study the neuronal expression of Fos, the protein product of c-fos, was used to study changes in neuronal activity in nerve terminal regions of the ascending dopaminergic system during nicotine withdrawal. Rats were infused for 14 days
Acetylcholine affects osteocytic MLO-Y4 cells via acetylcholine receptors
Ma Y, et al.
Molecular and cellular endocrinology, 384(1-2), 155-164 (2014)
Ver todos los artículos relacionados